The transglutaminase 2 gene is aberrantly hypermethylated in glioma

Lisa M. Dyer, Kevin Schooler, Lingbao Ai, Corinne Klop, Jingxin Qiu, Keith D. Robertson, Kevin D. Brown

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5′ flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.

Original languageEnglish (US)
Pages (from-to)429-440
Number of pages12
JournalJournal of Neuro-Oncology
Volume101
Issue number3
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Glioma
Genes
Brain Neoplasms
Doxorubicin
decitabine
Epigenomics
transglutaminase 2
Neoplasms
trichostatin A
Lomustine
Proteins
Histone Deacetylase Inhibitors
Transglutaminases
5' Flanking Region
Immunoblotting
Methylation
Extracellular Matrix
Databases
Breast Neoplasms
Phenotype

Keywords

  • Drug resistance
  • Epigenetic silencing
  • Extra cellular matrix
  • Glioma
  • Tumor invasiveness

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Dyer, L. M., Schooler, K., Ai, L., Klop, C., Qiu, J., Robertson, K. D., & Brown, K. D. (2011). The transglutaminase 2 gene is aberrantly hypermethylated in glioma. Journal of Neuro-Oncology, 101(3), 429-440. https://doi.org/10.1007/s11060-010-0277-7

The transglutaminase 2 gene is aberrantly hypermethylated in glioma. / Dyer, Lisa M.; Schooler, Kevin; Ai, Lingbao; Klop, Corinne; Qiu, Jingxin; Robertson, Keith D.; Brown, Kevin D.

In: Journal of Neuro-Oncology, Vol. 101, No. 3, 02.2011, p. 429-440.

Research output: Contribution to journalArticle

Dyer, LM, Schooler, K, Ai, L, Klop, C, Qiu, J, Robertson, KD & Brown, KD 2011, 'The transglutaminase 2 gene is aberrantly hypermethylated in glioma', Journal of Neuro-Oncology, vol. 101, no. 3, pp. 429-440. https://doi.org/10.1007/s11060-010-0277-7
Dyer LM, Schooler K, Ai L, Klop C, Qiu J, Robertson KD et al. The transglutaminase 2 gene is aberrantly hypermethylated in glioma. Journal of Neuro-Oncology. 2011 Feb;101(3):429-440. https://doi.org/10.1007/s11060-010-0277-7
Dyer, Lisa M. ; Schooler, Kevin ; Ai, Lingbao ; Klop, Corinne ; Qiu, Jingxin ; Robertson, Keith D. ; Brown, Kevin D. / The transglutaminase 2 gene is aberrantly hypermethylated in glioma. In: Journal of Neuro-Oncology. 2011 ; Vol. 101, No. 3. pp. 429-440.
@article{72b09bfbb4aa43f38d7b1692c5eb6041,
title = "The transglutaminase 2 gene is aberrantly hypermethylated in glioma",
abstract = "Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5′ flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.",
keywords = "Drug resistance, Epigenetic silencing, Extra cellular matrix, Glioma, Tumor invasiveness",
author = "Dyer, {Lisa M.} and Kevin Schooler and Lingbao Ai and Corinne Klop and Jingxin Qiu and Robertson, {Keith D.} and Brown, {Kevin D.}",
year = "2011",
month = "2",
doi = "10.1007/s11060-010-0277-7",
language = "English (US)",
volume = "101",
pages = "429--440",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - The transglutaminase 2 gene is aberrantly hypermethylated in glioma

AU - Dyer, Lisa M.

AU - Schooler, Kevin

AU - Ai, Lingbao

AU - Klop, Corinne

AU - Qiu, Jingxin

AU - Robertson, Keith D.

AU - Brown, Kevin D.

PY - 2011/2

Y1 - 2011/2

N2 - Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5′ flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.

AB - Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5′ flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2′-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.

KW - Drug resistance

KW - Epigenetic silencing

KW - Extra cellular matrix

KW - Glioma

KW - Tumor invasiveness

UR - http://www.scopus.com/inward/record.url?scp=79952196448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952196448&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0277-7

DO - 10.1007/s11060-010-0277-7

M3 - Article

C2 - 20596752

AN - SCOPUS:79952196448

VL - 101

SP - 429

EP - 440

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -